Drug Discovery World: Are TILs the next big thing in cancer treatment?

Sep 1, 2024

DDW’s Megan Thomas speaks with Dr Chantale Bernatchez, Director of Cell Therapy Process Development at CTMC, about tumour infiltrating lymphocyte (TIL) therapy and what’s on the horizon for this new class of cell therapy.

Article Link: https://www.ddw-online.com/ddw-fall-2024-31591-202409/

Part 2: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez

May 7, 2026

When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from...

Part 1: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez

May 5, 2026

The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the...

Base to Base biotech podcast #55: The circular supply chain

Apr 17, 2026

CTMC is a joint venture between Resilience and the MD Anderson Cancer Center. It works like an internal manufacturing group, adapting to change...

Back

Drug Discovery World: Are TILs the next big thing in cancer treatment?

Recent News

Part 2: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez

Part 1: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez

Base to Base biotech podcast #55: The circular supply chain

Explore CTMC

Resources + Support

Contact Us